Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 21-24 are currently pending in the instant application. Applicants have canceled claims 1-20 and added new claims 21-24 in an amendment filed on February 27, 2025. Claims 21-24 are rejected in this Office Action.
I. Priority
The instant application is a CON of 17/338,368, filed on June 3, 2021 PAT 12,221,433 which is a CON of 16/888,197, filed on May 29, 2020 ABN which is a CON of 16/446,360, filed on June 19, 2019 PAT 10,717,722 which is a CON of PCT/US2019/037067, filed on June 13, 2019 which claims benefit of US Provisional Application 62/684,681, filed on June 13, 2018.
II. Information Disclosure Statement
The information disclosure statement (IDS) submitted on February 27, 2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner.
III. Rejections
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.
Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).
Claims 21-24 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,221,433. Although the conflicting claims are not identical, they are not patentably distinct from each other because:
Applicants claim
PNG
media_image1.png
608
806
media_image1.png
Greyscale
Determining the Scope and Content of the Issued Patent
Claim 1 of the issued patent claims
PNG
media_image2.png
280
312
media_image2.png
Greyscale
PNG
media_image3.png
267
289
media_image3.png
Greyscale
Ascertaining the Differences Between the Instant Application and the Issued Patent
The instant application claims a kit comprising the same compound that the issued patent’s claim is drawn to.
Finding Prima Facie Obviousness
The scope of the compound in the patented claim 1 and the scope of the claims 21-24 of the instant application overlap and include patented subject matter in the instant claims. Therefore, one of ordinary skill in the art would be motivated to prepare and claim the scope of the compounds in the issued patent again in the instant application since the scope already patented falls within the full scope of the instant claims 21-24. As a result, the claims are rejected under obviousness-type double patenting.
Claims 21-24 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 10,717,722. Although the conflicting claims are not identical, they are not patentably distinct from each other because:
Applicants claim
PNG
media_image1.png
608
806
media_image1.png
Greyscale
Determining the Scope and Content of the Issued Patent
Claim 1 of the issued patent claims
PNG
media_image4.png
536
277
media_image4.png
Greyscale
PNG
media_image5.png
760
541
media_image5.png
Greyscale
PNG
media_image6.png
716
412
media_image6.png
Greyscale
Ascertaining the Differences Between the Instant Application and the Issued Patent
The instant application claims a kit comprising the same compound that the issued patent’s claim is drawn to in claim 9.
Finding Prima Facie Obviousness
The scope of the compound in the patented claims 1-9 and the scope of the claims 21-24 of the instant application overlap and include patented subject matter in the instant claims. Therefore, one of ordinary skill in the art would be motivated to prepare and claim the scope of the compounds in the issued patent again in the instant application since the scope already patented falls within the full scope of the instant claims 21-24. As a result, the claims are rejected under obviousness-type double patenting.
35 USC § 103 - OBVIOUSNESS REJECTION
The following is a quotation of 35 U.S.C. § 103(a) that forms the basis for all
obviousness rejections set forth in this Office action:
(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
Graham v. John Deere Co. set forth the factual inquiries necessary to determine obviousness under 35 U.S.C. §103(a). See Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966). Specifically, the analysis must employ the following factual inquiries:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 21-24 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Wang, et al. (US 2012/0189539 A1) in view of Abu-Jaish, et al. and Wang, et al. (US 2014/0199234 A1). Applicants claim
PNG
media_image1.png
608
806
media_image1.png
Greyscale
.
The Scope and Content of the Prior Art (MPEP §2141.01)
Wang, et al. (US 2012/0189539 A1) teaches BCL-2/BCL-XL inhibitors. The invention is represented by the general formula:
PNG
media_image7.png
326
148
media_image7.png
Greyscale
PNG
media_image8.png
332
305
media_image8.png
Greyscale
PNG
media_image9.png
596
358
media_image9.png
Greyscale
(see page 8) and further teaches the species
PNG
media_image10.png
256
464
media_image10.png
Greyscale
(See compound 205, page 95).
Abu-Jaish, et al. teaches prodrugs and more specifically the use of a phosphate prodrug which is linked to a free hydroxyl group and increases the aqueous solubility of the compound (see page 14).
Wang, et al. (US 2014/0199234 A1) which teaches BCL-2/BCL-XL inhibitors with similar structures that have a hydroxyl group phosphorylated such as the compound
PNG
media_image11.png
302
386
media_image11.png
Greyscale
(see compound 3, page 9) which maintains the BCL-2/BCL-XL inhibitory activity.
The Difference Between the Prior Art and the Claims (MPEP §2141.02)
The difference between the prior art of Wang, et al. (US 2012/0189539 A1) and the instant compounds is that the instant compound has the
PNG
media_image12.png
52
98
media_image12.png
Greyscale
group phosphorylated as a prodrug whereas the prior art’s compound does not. The other prior art references teaches the use of a phosphate group on free hydroxyl groups as a prodrug.
Prima Facie Obviousness-The Rational and Motivation (MPEP §2142-2413)
In In re Thornberg, 103 F. 2s 387 (CCPA 1966), it was well established that in determining obviousness, a combination of references need not result precisely in applicant’s structure. Rather, the question is whether the invention would have been obvious in light of the combination. The prior art teaches the compound
PNG
media_image10.png
256
464
media_image10.png
Greyscale
which is similar to the claimed compound
PNG
media_image13.png
205
471
media_image13.png
Greyscale
which is a prodrug of the prior art’s compound. It is well known in the art to prepare phosphate prodrugs of well-known compounds for the purpose of increasing the water solubility of the compound as taught in the Abu-Jaish, et al. reference. The second Wang, et al .reference teaches compounds with similar structures and the same utility that have a phosphate group attached the same group as seen in the instant compound and the activity was maintained. Therefore, it would be within one of ordinary skill in the art to prepare a phosphate prodrug of the known compound
PNG
media_image10.png
256
464
media_image10.png
Greyscale
as a BCL-2 inhibitor having increased aqueous solubility with a reasonable expectation for success. Phosphate prodrugs are well known in the art and would be obvious to prepare. Therefore, it would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to prepare a phosphate prodrug of
PNG
media_image10.png
256
464
media_image10.png
Greyscale
based on the teachings of the preferred embodiments in the prior art references. A strong prima facie obviousness has been established.
IV. Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626